ArticleHuman vaccines & immunotherapeutics2021
Hypothetical assessment of efficiency, willingness-to-accept and willingness-to-pay for dengue vaccine and treatment: a contingent valuation survey in Bangladesh.
Article in Human vaccines & immunotherapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 21 citations in OpenAlex.
- Willingness to accept the Dengue vaccine among adult Malaysians - An online survey.Human vaccines & immunotherapeutics · 2026Article
- Optimising pandemic response through vaccination strategies using neural networks.Scientific reports · 2026Article
- The annual recurrence of dengue in Bangladesh: A persistent threat.IJID regions · 2026Review
- Willingness to pay for a dengue vaccine in Iran: Insights from a contingent valuation study.PLoS neglected tropical diseases · 2026Article
- Unveiling the complexity of vaccine hesitancy: A narrative review focusing on dengue vaccination.Human vaccines & immunotherapeutics · 2025Review
- Assessment of determinant factors of willingness to pay for dengue vaccine: multicenter and cross-sectional study in Southeast Sulawesi, Indonesia.Clinical and experimental vaccine research · 2025Article
- Evaluating socioeconomic influences on Nipah virus vaccination decisions in Bangladesh through machine learning.Journal of health, population, and nutrition · 2025Article
- Modelling the impact of human behavior using a two-layer Watts-Strogatz network for transmission and control of Mpox.BMC infectious diseases · 2024Article
- Parents' intention to vaccinate their preschool children against COVID-19: Combining the health belief model and the theory of planned behavior.Human vaccines & immunotherapeutics · 2023Article
- Article
- Article
- Cost-Effectiveness of COVID-19 Sequential Vaccination Strategies in Inactivated Vaccinated Individuals in China.Vaccines · 2022Article
- Article
- Willingness to Pay for a COVID-19 Vaccine.Applied health economics and health policy · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In 2019, Bangladesh has grappled with a record-breaking surge in dengue fever, experiencing the highest number of dengue cases since the year 2000. Together, the intensification of dengue fever combined with a lack of dengue vaccines and appropriate medicines is expected to further the public and government's interests in appropriate and potential dengue vaccines to control the epidemic. We considered people's characteristics, dengue experience, and knowledge to assess their willingness-to-accept (WTA) and willingness-to-pay (WTP) for a hypothetical dengue vaccine and ex-post treatment in Bangladesh (June-July 2019). This study implemented a contingent valuation (CV) method with 3,251 respondents in 10 different locations of Bangladesh. All respondents participated in a hypothetical dengue vaccine scenario consisting of 65% (vaccine A), 80% (vaccine B), and 95% (vaccine C) effectiveness levels with three doses of each vaccine and ex-post dengue treatment. Around 71.2% of respondents were willing to pay for at least one of the hypothetical vaccines: A, B, or C. The average WTPs of the three vaccines amounted to US$ 47.0, US$ 66.0, and US$ 89.0, which were defined as the total cost of the doses necessary to obtain immunity. In Bangladesh, there is a significant demand for low-priced dengue vaccines, which was proven by people's higher acceptance of vaccination practices. Though dengue vaccines are not yet available in Bangladesh, this study provides significant support that both the government and private sectors should work together to develop a reliable and affordable dengue vaccine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.